News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Teck reported Q2 adjusted EBITDA of CAD 2.2 billion.
  • Teck posted adjusted profit attributable of CAD 948 million.
  • Higher copper production and record copper prices drove Teck's results.
  • Teck advanced its planned merger with Anglo American.
  • Renesas acquired Wolfspeed assets, positioning for automotive and power semiconductor growth.
  • Analyst upgraded Renesas to Buy, targeting a mid-term rebound to $15.50.

Latest Articles

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) announced its 2026 Annual Meeting of Stockholders will be held virtually on August 24, 2026. The company outlined deadlines for stockholders to submit proposals and nominations compliant with SEC rules and its bylaws. Tevogen emphasizes its integrated healthcare model focusing on biotechnology, AI, and healt…

Gold Pauses as Waller's Hawkish Tone Counters Middle East Safe-Haven Demand

Gold Pauses as Waller's Hawkish Tone Counters Middle East Safe-Haven Demand

Gold prices changed little on Tuesday as markets balanced rising geopolitical strain in the Middle East against signals from a Federal Reserve governor that higher interest rates may be needed if inflation proves broad-based. Spot gold dipped marginally while futures also edged lower, with investors awaiting June U.S. consumer price data and congre…

Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

Autonomix Medical, a Nasdaq-listed medical device company, announced a $2.6 million warrant inducement agreement that will result in the exercise of existing warrants at a reduced price and issuance of new warrants to the investor. The transaction is expected to close by mid-July 2026, providing the company with additional funding to support develo…

Chewy looks cheap on the surface — but the fundamentals say caution

Chewy looks cheap on the surface — but the fundamentals say caution

Chewy (CHWY) has fallen from its 52-week highs and trades near $20, a level that tempts bargain hunters. On closer inspection the company’s liquidity profile, mixed guidance, and a valuation that still embeds aggressive expectations argue that the recent drop is not an obvious buy. This trade idea lays out a mid-term short with a clear entry, stop …

Oil Rally Continues as U.S. Reimposes Maritime Blockade on Iran

Oil Rally Continues as U.S. Reimposes Maritime Blockade on Iran

Oil prices climbed further in Asian trading after a near 10% spike in the previous session, following the U.S. announcement that it will reinstate a naval blockade on Iran and levy a 20% charge on cargo passing through the Strait of Hormuz. The move, accompanied by recent attacks and counterattacks in the Gulf region, has heightened investor concer…

Yext Director Daniel Englander Acquires $397,909 in Company Stock

Yext Director Daniel Englander Acquires $397,909 in Company Stock

Daniel J. Englander, a director at Yext, Inc. (NYSE:YEXT), recently executed a significant insider purchase, acquiring 76,190 shares of the company’s common stock on July 13, 2026. The total transaction value reached $397,909, with shares bought at a weighted average price of $5.2226. This acquisition brings Englander’s direct holdings in Yext to 1…

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited announced it has achieved its target enrollment of 300 patients in its pivotal Phase 3 clinical trial for rexlemestrocel-L, an allogeneic cellular medicine for chronic low back pain (CLBP) due to degenerative disc disease. The trial is designed to confirm pain reduction and functional improvements. The therapy has received FDA RMA…

Planet Labs CEO Offloads $5.18M in Equity Under Pre-Arranged Plan

Planet Labs CEO Offloads $5.18M in Equity Under Pre-Arranged Plan

Marshall William Spencer, co-founder and chief executive officer of Planet Labs PBC, executed a sale of 200,000 shares of the company’s Class A Common Stock on July 10, 2026. The transaction, valued at approximately $5,183,940, was conducted under a Rule 10b5-1 trading plan established on July 12, 2025. The sale occurred at a weighted average price…

Planet Labs Executive Offloads Shares Amid Valuation Debate and Expansion

Planet Labs Executive Offloads Shares Amid Valuation Debate and Expansion

Planet Labs PBC (NYSE: PL) co-founder and Chief Strategy Officer Robert H. Schingler executed a significant stock sale on July 10, 2026, disposing of 89,593 Class A Common Stock shares for approximately $2.32 million. The transaction, conducted at $25.9197 per share, involved both direct holdings and shares held indirectly through the Ulysses Trust…

Heartflow Executive Unloads Shares Under Pre-Arranged Plan

Heartflow Executive Unloads Shares Under Pre-Arranged Plan

Heartflow Inc. CEO John C.M. Farquhar executed a sale of 22,562 shares on July 10, 2026, totaling $626,095 at $27.75 per share. This transaction occurred under a Rule 10b5-1 plan established in September 2025. The sale coincides with positive financial developments, including a first-quarter 2026 earnings beat and a sustained Overweight rating from…

Chewy: Underrated Cash Machine With Reliable Autoship Growth

Chewy: Underrated Cash Machine With Reliable Autoship Growth

Chewy is a digital-first pet retailer trading near $20 with steady revenue and margin expansion, strong autoship recurring revenue, and improving free cash flow. The stock looks actionable on a long-term horizon after the June guidance reset; this trade plan targets recovery toward higher multiples while protecting the downside at the 52-week low.

Buying Shake Shack Into Guidance-Driven Weakness: Tactical Swing Trade

Buying Shake Shack Into Guidance-Driven Weakness: Tactical Swing Trade

Shake Shack (SHAK) has been punished after a guidance trim and margin compression, creating a tactical buying opportunity for risk-tolerant traders. The business still shows mid-teens top-line growth and an aggressive unit expansion plan; valuations have reset to levels that reward a recovery in margins. Enter on a dip to $56.50 with a stop under t…

Glaukos CFO Executes Pre-Arranged Stock Transactions Near 52-Week High

Glaukos CFO Executes Pre-Arranged Stock Transactions Near 52-Week High

Glaukos Corp (NASDAQ: GKOS) Senior Vice President and Chief Financial Officer Alex R. Thurman recently completed a series of stock transactions under a pre-arranged trading plan. The CFO exercised stock options and simultaneously sold the resulting shares, totaling $1.55 million in sales. These moves come as the company's stock trades near its 52-w…

Arista Networks Executive Trims Holdings Amid Strong Quarterly Results

Arista Networks Executive Trims Holdings Amid Strong Quarterly Results

Arista Networks CEO Jayshree Ullal executed a $45.6 million sale of 242,422 shares on July 9, 2026, through pre-arranged trusts. The transaction occurred near the stock's 52-week high, following a 67% annual gain. Despite the sales, Ullal retains significant indirect holdings. The divestment coincides with Arista's Q1 2026 earnings beat, strong rev…

Kodiak Gas Services Executive Offloads Shares Under Pre-Arranged Plan

Kodiak Gas Services Executive Offloads Shares Under Pre-Arranged Plan

William Chad Lenamon, Executive Vice President and Chief Operating Officer at Kodiak Gas Services, Inc. (NASDAQ:KGS), sold 1,000 shares of company stock on July 13, 2026, generating proceeds of $67,790. The transaction was executed at $67.79 per share through a 10b5-1 trading plan established on March 13, 2026. Following the sale, Lenamon retains d…